Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Ellis SG, et al. Among authors: kabour a. N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12. N Engl J Med. 2015. PMID: 26457558 Free article. Clinical Trial.
Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial.
Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, Dauber IM, Rabinowitz AC, Ball MW, Bertolet B, Kabour A, Foster MC, Wang JC, Underwood P, Dawkins KD. Kereiakes DJ, et al. Among authors: kabour a. J Am Coll Cardiol. 2010 Jul 20;56(4):264-71. doi: 10.1016/j.jacc.2010.04.011. Epub 2010 May 20. J Am Coll Cardiol. 2010. PMID: 20493653 Free article. Clinical Trial.
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
Waksman R, Piegari GN, Kabour A, Cannon L, Wang J, Adams G, Solankhi N, Smeglin A, Kereiakes DJ, Leiboff R, Spad MA, Torguson R, Chandra N, Bastian R, DeGroot J, Kayo MW, Stoll HP, Garcia-Garcia HM. Waksman R, et al. Among authors: kabour a. Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):475-481. doi: 10.1016/j.carrev.2017.07.017. Epub 2017 Jul 31. Cardiovasc Revasc Med. 2017. PMID: 28923692 Clinical Trial.
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Kereiakes DJ, et al. Among authors: kabour a. J Am Coll Cardiol. 2017 Dec 12;70(23):2852-2862. doi: 10.1016/j.jacc.2017.10.010. Epub 2017 Oct 31. J Am Coll Cardiol. 2017. PMID: 29100702 Free article. Clinical Trial.
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J Jr, Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Généreux P, Kereiakes DJ; ABSORB IV Investigators. Stone GW, et al. Among authors: kabour a. Lancet. 2018 Oct 27;392(10157):1530-1540. doi: 10.1016/S0140-6736(18)32283-9. Epub 2018 Sep 25. Lancet. 2018. PMID: 30266412 Clinical Trial.
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, Tan SH, Ediebah DE, Simonton C, Stone GW; ABSORB III Investigators. Kereiakes DJ, et al. Among authors: kabour a. Circulation. 2019 Dec 3;140(23):1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584. Epub 2019 Sep 25. Circulation. 2019. PMID: 31553222
5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique.
Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Kabour A, Piegari G, Cavendish J, Bertolet B, Stockelman KA, West NEJ, Ben-Yehuda O, Choi JW, Marx SO, Spertus JA, Ellis SG; ABSORB IV Investigators. Stone GW, et al. Among authors: kabour a. J Am Coll Cardiol. 2023 Jul 18;82(3):183-195. doi: 10.1016/j.jacc.2023.05.003. Epub 2023 May 17. J Am Coll Cardiol. 2023. PMID: 37207924 Free article. Clinical Trial.
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy.
Patel KP, Lansky AJ, Kereiakes DJ, Windecker S, Cristea E, Pietras C, Dressler O, Issever MO, Curtis M, Bertolet B, Zidar JP, Smits PC, Jiménez Díaz VA, McLaurin B, Brogno DA, Janssens L, Vrolix MC, Gómez-Blázquez I, Sahul ZH, Kabour A, Salido L, Cleman M, Saito S, Leon MB, Baumbach A; PIONEER III Trial Investigators. Patel KP, et al. Among authors: kabour a. J Soc Cardiovasc Angiogr Interv. 2022 Jan 30;1(1):100004. doi: 10.1016/j.jscai.2021.100004. eCollection 2022 Jan-Feb. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39130138 Free PMC article.
54 results